Background stories of how others approached and experienced their European Horizon funding trajectory.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
Read the full article for detailsThe Horizon2020 twinning project ScreenME has as its objective to enhance excellence in screen media entrepreneurship at Tallinn University (TLU). To do so, ScreenME has established a network of universities across Europe that aim to improve research into and teaching of entrepreneurship for the screen media industry. ScreenME will develop a teaching course and will kick off research initiatives and projects on entrepreneurial activities in media organisations. The research group on ‘Studies in Media, Innovation and Technology (SMIT)’ of the Vrije Universiteit Brussel (VUB) is partner in the network and is involved in two cross-cutting activities of the project: support for early stage researchers and developing stakeholder involvement.